Results 1 to 10 of about 1,745 (114)

Bridging Research and Clinical Practice: Automated [⁶⁸Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging. [PDF]

Pharmaceuticals (Basel)
Background/Objectives: Fibroblast activation protein (FAP) has emerged as a promising target for oncologic molecular imaging due to its high expression in cancer-associated fibroblasts and low presence in healthy tissues.
Santos CRP, Malavolta L, Mejia J, Lima Fuscaldi L, Yamaga LYI, Barboza MF.   +5 more
europepmc   +2 more sources

Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence. [PDF]

EJNMMI Radiopharm Chem
Background Enantiomeric composition may impact binding and potentially performance of a drug product but is not routinely tested and minimum acceptance criteria are not always established.
Staniszewska M, Hübner R, Locatelli C, Howard D, Forni M, Man F, Schoultz BW, Nuruddin S, Norberg-Schulz Hagen IS, Mosessian S, Herrmann K, von Kiedrowski V, Lückerath K.   +12 more
europepmc   +2 more sources

Diagnostic value of [⁶⁸Ga]Ga-FAPI-46 PET in comparison to [¹⁸F]FDG PET in triple-negative breast cancer and potential for theranostic application. [PDF]

Sci Rep
This single-center subgroup analysis of a prospective trial (NCT04571086) at University Hospital Essen investigated tumor uptake and detection rates of [68Ga]Ga-FAPI-46- versus [18F]FDG PET in triple-negative breast cancer (TNBC) patients undergoing ...
Küper AT, Ciuciulkaite I, Welt A, Vaz SC, Mavroeidi IA, Hamacher R, Demmert T, Pabst KM, Moraitis A, Djaileb L, Seifert R, Umutlu L, Schuler M, Herrmann K, Fendler WP, Kümmel S, Kersting D.   +16 more
europepmc   +2 more sources

Automated Synthesis of [⁶⁸Ga]Ga-FAPI-46 on a Scintomics GRP Synthesizer. [PDF]

Pharmaceuticals (Basel), 2023
[68Ga]Ga-FAPI-46 is a radiolabelled fibroblast activation protein inhibitor that selectively binds to fibroblast activation protein (FAP), which is overexpressed by cancer-associated fibroblasts (CAFs) in the tumour microenvironment.
Plhak E, Pichler C, Dittmann-Schnabel B, Gößnitzer E, Aigner RM, Stanzel S, Kvaternik H.   +6 more
europepmc   +2 more sources

Correlation of apparent diffusion coefficient, FAP expression in IHC and [⁶⁸Ga]Ga‑FAPI‑46 uptake using integrated PET/MRI in high-grade soft tissue sarcoma: initial exploratory results. [PDF]

EJNMMI Res
Background Fibroblast activation protein inhibitor (FAPI)-targeted positron emission tomography (PET) has emerged as a promising imaging approach in soft tissue sarcomas (STS), whereas magnetic resonance imaging (MRI) remains the diagnostic standard.
Hettler M, Menge F, Ludwig J, Nörenberg D, Schönberg SO, Hinterberger A, Wängler B, Wängler C, Rudolf H, Davarci G, Cieslik P, Cotarelo CL, Harbrücker M, Reißfelder C, Jakob J, Kunz WG, Grawe F.   +16 more
europepmc   +2 more sources

Microfluidic-based production of [⁶⁸Ga]Ga-FAPI-46 and [⁶⁸Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer. [PDF]

EJNMMI Radiopharm Chem, 2023
Background The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE.
Mallapura H, Ovdiichuk O, Jussing E, Thuy TA, Piatkowski C, Tanguy L, Collet-Defossez C, Långström B, Halldin C, Nag S.   +9 more
europepmc   +2 more sources

Fully automated radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 with cyclotron produced gallium. [PDF]

EJNMMI Radiopharm Chem, 2023
Background Radiopharmaceuticals capable of targeting the fibroblast activation protein have become widely utilized in the research realm as well as show great promise to be commercialized; with [68Ga]Ga-FAPI-46 being one of the most widely utilized ...
Rosenberg AJ, Cheung YY, Liu F, Sollert C, Peterson TE, Kropski JA.   +5 more
europepmc   +2 more sources

Comparison of diagnostic performance of [⁶⁸Ga]-Ga-FAPI-46 and [¹⁸F]-FDG PET/CT imaging for the detection of lesions and disease staging in patients with breast cancer. [PDF]

Asia Ocean J Nucl Med Biol
Objective(s):  To compare the diagnostic performance of [68Ga]-Ga-FAPI-46 and [18F]-FDG PET/CT imaging for the detection of lesions and disease staging in breast cancer.Methods: Twelve female patients with breast cancer (mean age= 49.2±13.29 years) and ...
Radmehr K, Farzanefar S, Abbasi M, Salehi Y, Karamzade-Ziarati N, Emami-Ardekani A, Manafi-Farid R, Vahidfar N, Beiki D.   +8 more
europepmc   +2 more sources

Comparison of early and late ⁶⁸Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas. [PDF]

Sci Rep, 2023
Positron emission tomography with 68Gallium (68Ga) labeled inhibitors of fibroblast activation protein (68Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC).
Hoppner J, van Genabith L, Hielscher T, Heger U, Sperling L, Colbatzky T, Gutjahr E, Lang M, Pausch T, Spektor AM, Glatting FM, Liermann J, Hackert T, Kratochwil C, Giesel FL, Haberkorn U, Röhrich M.   +16 more
europepmc   +2 more sources

The synergy of ¹⁷⁷Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model. [PDF]

Biomed J
Background: Given the heterogeneity and high mortality associated with metastatic soft tissue sarcoma, this study aims to evaluate the therapeutic efficacy of combining 177Lu-FAPI-46 with Pazopanib against this malignancy.
Tseng JR, Hsu CL, Hsieh HH, Ho KC, Chung YH, Wu CY.   +5 more
europepmc   +2 more sources